Broderick Peter, Dobbins Sara E, Chubb Daniel, Kinnersley Ben, Dunlop Malcolm G, Tomlinson Ian, Houlston Richard S
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh.
Gastroenterology. 2017 Jan;152(1):75-77.e4. doi: 10.1053/j.gastro.2016.09.041. Epub 2016 Oct 3.
High-throughput sequencing analysis has accelerated searches for genes associated with risk for colorectal cancer (CRC); germline mutations in NTHL1, RPS20, FANCM, FAN1, TP53, BUB1, BUB3, LRP6, and PTPN12 have been recently proposed to increase CRC risk. We attempted to validate the association between variants in these genes and development of CRC in a systematic review of 11 publications, using sequence data from 863 familial CRC cases and 1604 individuals without CRC (controls). All cases were diagnosed at an age of 55 years or younger and did not carry mutations in an established CRC predisposition gene. We found sufficient evidence for NTHL1 to be considered a CRC predisposition gene-members of 3 unrelated Dutch families were homozygous for inactivating p.Gln90Ter mutations; a Canadian woman with polyposis, CRC, and multiple tumors was reported to be heterozygous for the inactivating NTHL1 p.Gln90Ter/c.709+1G>A mutations; and a man with polyposis was reported to carry p.Gln90Ter/p.Gln287Ter; whereas no inactivating homozygous or compound heterozygous mutations were detected in controls. Variants that disrupted RPS20 were detected in a Finnish family with early-onset CRC (p.Val50SerfsTer23), a 39-year old individual with metachronous CRC (p.Leu61GlufsTer11 mutation), and a 41-year-old individual with CRC (missense p.Val54Leu), but not in controls. We therefore found published evidence to support the association between variants in NTHL1 and RPS20 with CRC, but not of other recently reported CRC susceptibility variants. We urge the research community to adopt rigorous statistical and biological approaches coupled with independent replication before making claims of pathogenicity.
高通量测序分析加速了对与结直肠癌(CRC)风险相关基因的搜索;最近有人提出,NTHL1、RPS20、FANCM、FAN1、TP53、BUB1、BUB3、LRP6和PTPN12中的种系突变会增加患CRC的风险。我们试图通过对11篇出版物的系统评价来验证这些基因中的变异与CRC发生之间的关联,使用来自863例家族性CRC病例和1604名无CRC个体(对照)的序列数据。所有病例均在55岁或更年轻时被诊断出,且未携带已确定的CRC易感基因中的突变。我们发现有充分证据表明NTHL1可被视为CRC易感基因——3个无亲缘关系的荷兰家族成员为失活的p.Gln90Ter突变纯合子;据报道,一名患有息肉病、CRC和多种肿瘤的加拿大女性为失活的NTHL1 p.Gln90Ter/c.709+1G>A突变杂合子;据报道,一名患有息肉病的男性携带p.Gln90Ter/p.Gln287Ter;而在对照中未检测到失活的纯合子或复合杂合子突变。在一个患有早发性CRC的芬兰家族(p.Val50SerfsTer23)、一名患有异时性CRC的39岁个体(p.Leu61GlufsTer11突变)和一名患有CRC的41岁个体(错义p.Val54Leu)中检测到了破坏RPS20的变异,但在对照中未检测到。因此,我们发现已发表的证据支持NTHL1和RPS20中的变异与CRC之间的关联,但不支持其他最近报道的CRC易感变异。我们敦促研究界在提出致病性主张之前,采用严谨的统计和生物学方法并进行独立验证。